EVG Evgen Pharma

EQS-News: Evgen Pharma 'cash runway in pretty good shape'

EQS-News: Evgen Pharma PLC
Evgen Pharma 'cash runway in pretty good shape'

12.12.2022 / 12:53 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

12.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Evgen Pharma PLC
United States
ISIN: GB00BSVYN304
EQS News ID: 1510673

 
End of News EQS News Service

1510673  12.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1510673&application_name=news&site_id=research_pool
EN
12/12/2022

Underlying

EVGEvgen Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evgen Pharma

Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | DAT asset potential value highlighted

TheraCryf notes a recent article in Nature covering the issue of mental fatigue which is indicative of the commercial opportunity provided by the company's dopamine transporter (DAT) inhibitor, its second preclinical programme. The market for chronic fatigue treatment is estimated at US$1.2bn in 2024, rising to cUS$2.3bn by 2033, significantly higher than previously intimated. TheraCryf's DAT inhibitor has been demonstrated to be efficacious in treating animal models of fatigue dosed with the co...

12/18/25 December 18, 2025 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | 1H26 - Good progress on Ox-1; results as expected

TheraCryf's 1HFY26 results to September, confirm that the company is making strong progress towards clinical readiness for its Ox-1 lead clinical asset and the results were in line with expectations. There was a modest cash burn in the half of £0.7m, with cash and net cash ending the period at £3.5m. TheraCryf reiterated that it is funded through to the end of calendar 2026 when Ox-1 should be ready for clinical trials in humans, a key value inflection point. TheraCryf's valuation remains nugato...

12/03/25 December 3, 2025 1 EN
Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
EVG EVGEN PHARMA
MTEC MADE TECH GROUP...

Friday Take Away: 28 November 2025

Friday Takeaway—delving a little deeper into UK small caps Friday Takeaway from UK Small Caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 28th November 2025 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication. Top three shareholders are taken from the web...

EVG EVGEN PHARMA
MTEC MADE TECH GROUP PLC
11/28/25 November 28, 2025 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf (TCF) | AGM updates on OX-1 and SFX-01 programmes

TheraCryf held its AGM yesterday at which management emphasised its focus on brain disorders and specifically on advancing the Orexin (Ox-1) programme acquired in the Chronos transaction to clinical stage readiness by the end of calendar 2026, for which the company is now fully funded. The legacy synthetic Sulforaphane molecule (SFX-01) continues to be progressed in third-party funded programmes, most notably in the potential treatment for the brain cancer Glioblastoma at the Erasmus Medical Cen...

07/10/25 July 10, 2025 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf (TCF) | FY25 results: expanded portfolio; focus on Ox-1

TheraCryf has released results for the year to March 2025 with the next 12-18 months set to be pivotal for the company as it focuses on advancing its Orexin-1 (Ox-1) programme while the Sulforaphane (SFX-01) programmes continue with third party funding. During FY25, the company acquired Chronos Therapeutics, making it a multi-compound drug developer, and raised a total of £5.2m, gross, funding the Ox-1 programme through to clinical readiness while extending TheraCryf's cash runway to 4Q 2026. Th...

06/03/25 June 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch